Physician profile
Puliadi Jothikumar
NPI 1154429108
$3,337.76
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $543 · 2020: $742 · 2021: $874 · 2022: $448 · 2023: $554 · 2024: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $730.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $729.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $741.51 | 2019-2021 | |
| Novo Nordisk INC | $630.22 | 2019-2023 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $570.27 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $446.79 | 2019-2023 | Tradjenta, Jardiance |
| Lilly USA, LLC | $217.34 | 2019-2023 | Jardiance, Emgality |
| Janssen Pharmaceuticals, INC | $146.54 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $131.10 | 2019 | |
| Nestle Healthcare Nutrition INC. | $116.80 | 2021 | |
| Phathom Pharmaceuticals, INC. | $98.33 | 2024 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $50.78 | 2021 | |
| Pfizer INC. | $45.21 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $40.44 | 2021 | |
| Esperion Therapeutics, INC. | $35.48 | 2020 | |
| Amgen INC. | $24.73 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.22 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $21.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Puliadi Jothikumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.